Cargando…

Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein

Prevention efforts for respiratory syncytial virus (RSV) have been advanced due to the recent isolation and characterization of antibodies that specifically recognize the prefusion conformation of the RSV fusion (F) glycoprotein. These potently neutralizing antibodies are in clinical development for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gilman, Morgan S. A., Moin, Syed M., Mas, Vicente, Chen, Man, Patel, Nita K., Kramer, Kari, Zhu, Qing, Kabeche, Stephanie C., Kumar, Azad, Palomo, Concepción, Beaumont, Tim, Baxa, Ulrich, Ulbrandt, Nancy D., Melero, José A., Graham, Barney S., McLellan, Jason S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4498696/ https://www.ncbi.nlm.nih.gov/pubmed/26161532 http://dx.doi.org/10.1371/journal.ppat.1005035

Ejemplares similares

Transient opening of trimeric prefusion RSV F proteins
por: Gilman, Morgan S. A., et al.
Publicado: (2019)

Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state
por: Rossey, Iebe, et al.
Publicado: (2017)

Corrigendum: Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state
por: Rossey, Iebe, et al.
Publicado: (2017)

Structure-based design of prefusion-stabilized human metapneumovirus fusion proteins
por: Hsieh, Ching-Lin, et al.
Publicado: (2022)

Protection of calves by a prefusion-stabilized bovine RSV F vaccine
por: Zhang, Baoshan, et al.
Publicado: (2017)

A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism
por: Krarup, Anders, et al.
Publicado: (2015)

Structure-Based Design of Prefusion-Stabilized Filovirus Glycoprotein Trimers
por: Rutten, Lucy, et al.
Publicado: (2020)

Adjuvant Selection for Influenza and RSV Prefusion Subunit Vaccines
por: Isaacs, Ariel, et al.
Publicado: (2021)

Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation
por: Wrapp, Daniel, et al.
Publicado: (2020)

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
por: Wrapp, Daniel, et al.
Publicado: (2020)

The 3.1-Angstrom Cryo-electron Microscopy Structure of the Porcine Epidemic Diarrhea Virus Spike Protein in the Prefusion Conformation
por: Wrapp, Daniel, et al.
Publicado: (2019)

Fusing safety and efficacy: A maternal bivalent RSV prefusion F vaccine
por: Miller, Ann M., et al.
Publicado: (2023)

RSV A2-Based Prefusion F Vaccine Candidates Induce RSV A and RSV B Cross Binding and Neutralizing Antibodies and Provide Protection against RSV A and RSV B Challenge in Preclinical Models
por: Cox, Freek, et al.
Publicado: (2023)

Immunogenicity and protective efficacy of RSV G central conserved domain vaccine with a prefusion nanoparticle
por: Rainho-Tomko, Jennifer N., et al.
Publicado: (2022)

A human antibody potently neutralizes RSV by targeting the conserved hydrophobic region of prefusion F
por: Yi, Chunyan, et al.
Publicado: (2023)

Continuous flexibility analysis of SARS-CoV-2 spike prefusion structures
por: Melero, Roberto, et al.
Publicado: (2020)

Continuous flexibility analysis of SARS-CoV-2 Spike prefusion structures
por: Melero, Roberto, et al.
Publicado: (2020)

Improved epitope resolution of the prefusion trimer-specific antibody AM14 bound to the RSV F glycoprotein
por: Harshbarger, Wayne, et al.
Publicado: (2021)

The respiratory syncytial virus (RSV) prefusion F‐protein functional antibody repertoire in adult healthy donors
por: Andreano, Emanuele, et al.
Publicado: (2021)

Engineering, Structure and Immunogenicity of the Human Metapneumovirus F Protein in the Postfusion Conformation
por: Más, Vicente, et al.
Publicado: (2016)

1632. Bivalent RSV Prefusion F-Based Subunit Vaccine Generates High Neutralizing Titers in Older Adults
por: Fukushima, Yasushi, et al.
Publicado: (2023)

Nanoparticle display of prefusion coronavirus spike elicits S1-focused cross-reactive protection across divergent subgroups
por: Hutchinson, Geoffrey, et al.
Publicado: (2022)

Alternative conformations of a major antigenic site on RSV F
por: Jones, Harrison G., et al.
Publicado: (2019)

1936. Efficacy of One Dose of the Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Adults ≥ 60 Years of Age Persists for 2 RSV Seasons
por: Ison, Michael G, et al.
Publicado: (2023)

2755. Phase 1/2, First-in-Human Study of the Safety, Tolerability, and Immunogenicity of an RSV Prefusion F-Based Subunit Vaccine Candidate
por: Schmoele-Thoma, Beate, et al.
Publicado: (2019)

Structure-based Design of Prefusion-stabilized SARS-CoV-2 Spikes
por: Hsieh, Ching-Lin, et al.
Publicado: (2020)

A Protective and Safe Intranasal RSV Vaccine Based on a Recombinant Prefusion-Like Form of the F Protein Bound to Bacterium-Like Particles
por: Rigter, Alan, et al.
Publicado: (2013)

Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice
por: van der Fits, Leslie, et al.
Publicado: (2020)

Enhancing Anti-G Antibody Induction by a Live Single-Cycle Prefusion F—Expressing RSV Vaccine Improves In Vitro and In Vivo Efficacy
por: Lamichhane, Pramila, et al.
Publicado: (2022)

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes
por: Hsieh, Ching-Lin, et al.
Publicado: (2020)

Nanoparticle display of prefusion coronavirus spike elicits S1-focused cross-reactive antibody response against diverse coronavirus subgenera
por: Hutchinson, Geoffrey B., et al.
Publicado: (2023)

P19-23. Putative prefusion mechanism of HIV-1 Env revealed by ligand-induced quaternary alterations in o-gp140 trimers
por: Moscoso, CG, et al.
Publicado: (2009)

Structural basis for recognition of the central conserved region of RSV G by neutralizing human antibodies
por: Jones, Harrison G., et al.
Publicado: (2018)

Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18–50 Years and RSV-Seropositive Children 12–24 Months
por: Stuart, Arabella S V, et al.
Publicado: (2022)

Recombinant Soluble Respiratory Syncytial Virus F Protein That Lacks Heptad Repeat B, Contains a GCN4 Trimerization Motif and Is Not Cleaved Displays Prefusion-Like Characteristics
por: Widjaja, Ivy, et al.
Publicado: (2015)

Architecture of the SARS coronavirus prefusion spike
por: Beniac, Daniel R, et al.
Publicado: (2006)

1942. Potential Public Health Impact of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Maternal Vaccine for Prevention of RSV among US Infants
por: Hanau, Ahuva, et al.
Publicado: (2023)

LB745. Respiratory Syncytial Virus (RSV) Prefusion F Protein Candidate Vaccine (RSVPreF3 OA) is Efficacious in Adults ≥ 60 Years of Age (YOA)
por: Ison, Michael G, et al.
Publicado: (2022)

Recombinant Env proteins that bind the quaternary-specific, V1/V2-directed PGT antibodies
por: Gorman, J, et al.
Publicado: (2012)

Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus
por: Choi, Jang-Hoon, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6ijnt26l6j255hs07qgt11cl2b